Can maternal metformin protect the developing fetal brain?
Abstract
Background: Maternal diabetes is associated with an increased risk of autism spectrum disorder and attention-deficit hyperactivity disorder. Metformin has an emerging role as a neuroprotective agent, both in perinatal preclinical models and in nonobstetric clinical trials. Metformin crosses the placenta and fetal exposure has potential risks and benefits. New techniques allow for isolation of extracellular vesicles that originate from fetal neurons and cross the placenta into maternal blood, providing a window into ongoing neurodevelopment.
Objective: To determine if maternal treatment with metformin for maternal diabetes had beneficial effects on biomarkers of fetal brain health.
Study design: A nested case-control study was performed on maternal samples from a randomized controlled trial of metformin (1000 mg twice daily) + insulin vs insulin only for perinatal type 2 diabetes mellitus (n=40 in each group) or gestational diabetes mellitus. Fetal neuronally derived extracellular vesicles were purified from maternal serum collected at 24 to 30 weeks. Sirtuin-1, tumor necrosis factor-alpha and Bcl-2-associated X protein were quantified. Correlation between vesicle and fetal brain concentrations of biomarkers was validated in a second set of individuals undergoing voluntary pregnancy termination. Generalized linear modeling was performed to evaluate the effect of metformin treatment on fetal neuronal markers.
Results: In-utero exposure to metformin was associated with a 39%…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 40 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.